株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

A型インフルエンザウイルス H3N2亜型感染症:パイプライン製品の分析

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 369078
出版日 ページ情報 英文 131 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.57円で換算しております。
Back to Top
A型インフルエンザウイルス H3N2亜型感染症:パイプライン製品の分析 Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018
出版日: 2018年02月20日 ページ情報: 英文 131 Pages
概要

H3N2感染症は、インフルエンザウィルスの変異株であるH3N2ウィルスによって引き起こされます。症状は、咳、咽頭痛、鼻水・鼻づまり、悪寒、吐き気、嘔吐、あるいは下痢などが見られます。危険因子として年齢、喘息や糖尿病、心臓病、弱まった免疫機構、神経系あるいは神経発達的症状などといった慢性内科的疾患が挙げられます。治療は抗ウイルス薬や抗生物質を使います。

当レポートでは、A型インフルエンザウイルス H3N2亜型感染症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 調査範囲

A型インフルエンザウイルス H3N2亜型感染症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/研究機関で研究中の製品

治療薬開発に従事している企業

  • AbbVie Inc
  • AIMM Therapeutics B.V.
  • Aphios Corporation
  • Celltrion, Inc.
  • FluGen, Inc.
  • Glide Pharmaceutical Technologies Limited
  • ILiAD Biotechnologies, LLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medicago Inc.
  • MedImmune, LLC
  • Mucosis B.V.
  • NanoViricides, Inc.
  • OPKO Health, Inc.
  • Sarepta Therapeutics, Inc.
  • 武田薬品工業
  • VBI Vaccines Inc.
  • Visterra, Inc.
  • Zydus Cadila Healthcare Limited

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

目次
Product Code: GMDHC10173IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 7, 5, 16 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 2, 1, 1 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H3N2 Subtype Infections - Overview
    • Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Adimmune Corp
    • Aphios Corp
    • AusBio Ltd
    • BioCryst Pharmaceuticals Inc
    • BiondVax Pharmaceuticals Ltd
    • Cadila Healthcare Ltd
    • Celltrion Inc
    • Emergent BioSolutions Inc
    • FluGen Inc
    • Inovio Pharmaceuticals Inc
    • Jiangsu Kanion Pharmaceutical Co Ltd
    • Johnson & Johnson
    • Medicago Inc
    • MedImmune LLC
    • Mucosis BV (Inactive)
    • NanoViricides Inc
    • Novavax Inc
    • OPKO Health Inc
    • Sanofi
    • Sanofi Pasteur SA
    • Sarepta Therapeutics Inc
    • SK Chemicals Co Ltd
    • VBI Vaccines Inc
  • Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
    • APP-0205 - Drug Profile
    • APP-309 - Drug Profile
    • Aspidasept - Drug Profile
    • AV-5075S - Drug Profile
    • AV-5080 - Drug Profile
    • C-05 - Drug Profile
    • cetylpyridinium chloride - Drug Profile
    • CTP-27 - Drug Profile
    • Fluad (quadrivalent) - Drug Profile
    • Gamma-Flu - Drug Profile
    • influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
    • influenza [strain A/H3N2] vaccine - Drug Profile
    • influenza [strain A/H3N2] vaccine - Drug Profile
    • influenza [strain A/H3N2] vaccine - Drug Profile
    • influenza [strain A/H3N2v] vaccine - Drug Profile
    • influenza [strain A/H3N2v] vaccine - Drug Profile
    • influenza [strain H3N2] vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
    • influenza [strains A/H3N2 + A/H1N1] vaccine - Drug Profile
    • M-001 - Drug Profile
    • MD-2009 - Drug Profile
    • NBP-607 - Drug Profile
    • NEO-8877 - Drug Profile
    • NP-025 - Drug Profile
    • NSC-61610 - Drug Profile
    • NVINF-1 - Drug Profile
    • NVINF-2 - Drug Profile
    • Peptides for Influenza Infections - Drug Profile
    • peramivir - Drug Profile
    • pertussis [strain BPZE1] vaccine - Drug Profile
    • pimodivir hydrochloride - Drug Profile
    • PNSIA-28 - Drug Profile
    • PrEP-001 - Drug Profile
    • radavirsen - Drug Profile
    • REDEE FLU - Drug Profile
    • Small Molecules for RSV and Influenza A Infections - Drug Profile
    • Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile
    • UV-4B - Drug Profile
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
  • Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
  • Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by AusBio Ltd, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV (Inactive), H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top